British Biotech fails to redeem itself
Article Abstract:
Oxford, UK-based British Biotech has not convinced institutional and private investors that its troubles are over. Andrew Millar, the company's former head of clinical research, claimed that British Biotech had misled investors concerning the clinical prospects of its pancreatitis drug, Zacutex, The company issued a 31-page circular refuting these claims for shareholders.
Comment:
Has not convinced institutional and private investors that its troubles are over
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Hepatitis C collaboration
Article Abstract:
Ribozyme Pharmaceuticals and Eli Lilly have agreed to develop a therapeutic for the treatment of the hepatitis C virus infection. Ribozyme CEO Ralph Christofferson stated that developing a drug for the treatment of hepatitis C is a great challenge because of the speed with which it mutates.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Functional foods from biotech: An unappetizing prospect?
Article Abstract:
Major setbacks and disappointments faced by functional foods, which once promised to solve global malnutrition and put palatable options with healthful benefits, are reviewed.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: From renter to rentier in one generation. MEPC
- Abstracts: Unigate spreads it thickly. Treats: losing the lolly. Benefits of restructuring show through
- Abstracts: Marketing means knowing, doing it all. TQM connects all segments of marketing
- Abstracts: From high growth to new growth. Asset price inflation in Asia
- Abstracts: Profiting from transformation. Glossary